Massachusetts Biomedical Initiatives (MBI)’s Post

MBI is excited to share our 2023 Impact Report with you all! Check out what #impact MBI made last year, our 2023 #ChallengeGrants, updates on our #startups & #incubator, and our #goals for the future! Thank you for your years of #support, we can't wait to see what this year holds! #startupincubator #Woomentum #economicdevelopment #regional #advocacy #clusterbuilding #workforcedevelopment #nonprofit

#PantheonVision, a #medical #equipment manufacturing company located in #Maryland, secures $2.5 million in seed #funding. KeraLink International (KLI), a creative and progressive 501(c)(3) nonprofit organisation inspired by compassion and #empathy, competed in the round. The company plans to use the funds to expand its operations, its business reach, and its R&D division. Under the direction of CEO John Sheets, Ph.D., Pantheon eyesight is devoted to creating cutting-edge #bioengineered treatments that can heal corneal #blindness and give people across the world their #eyesight back. In order to enhance eye care globally and lessen dependency on donated #corneal tissue—which can often be unavailable in low- and middle-income countries (LMICs)—the business is developing #bioengineered implants. In the upcoming months, the company is going to #collaborate with the U.S. Food and Drug Administration (FDA) to guide plans for international product development. Dr. Sheets worked in the R&D departments at Alcon, Johnson & Johnson, Bausch & Lomb, and Hoya, among other companies. He oversaw the FDA's Office of Device #Evaluation as well. Pantheon Vision KeraLink International John Sheets, Ph.D. #pantheonvision #funding #startup

Here is an idea for International Women's Day. Make an investment that could make a difference in the future to someone you know, or someone in your family. Ablatus - creators of Luna are crowdfunding their latest raise on Crowdcube. They are developing a device for the much-improved treatment of Uterine Fibroids, and I'm invested. I know I could lose my investment, but it could also be a very successful one. As their CEO Chung Looi put it the other day in a great article "Women's Health is a necessity, not a charity". So, if you want to make a difference, take a look at this opportunity; it is close to its target now, so push it over the line today, and don't miss out! #womenshealth #internationalwomensday #investmentopportunities

✨ 𝗟𝗮𝘁𝗶𝗴𝗼 𝗕𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗦𝗲𝗰𝘂𝗿𝗲𝘀 $𝟭𝟯𝟱 𝗠𝗶𝗹𝗹𝗶𝗼𝗻 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 𝗳𝗼𝗿 𝗡𝗼𝗻-𝗢𝗽𝗶𝗼𝗶𝗱 𝗣𝗮𝗶𝗻 𝗠𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁! 🌐 𝗜𝗻 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟰, Latigo Biotherapeutics, Inc. raised $135 million in the US to create a non-opioid #medication. Latigo Biotherapeutics made its debut on Wednesday with LTG-001, a lead nav1.8 inhibitor that is presently undergoing testing on fit #volunteers. According to Latigo officials, the nav1.8 #inhibitor will be useful for treating both acute and chronic pain. The Lieber Institute for #Brain🧠 Development in #Baltimore provided some of the basic research for LTG-001, although the #preclinical study was carried out at #laboratories🧪 in Thousand Oaks, #California. Corner Ventures invested in the initial funding, which was co-led by 5AM Ventures and Foresite Capital. Officials at Latigo think that the $135 million funding would enable the organization to plan for the chronic pain research while finishing the current phase 1 trial and a potential phase 2 acute pain study. 𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗟𝗶𝗻𝗸𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉: https://bit.ly/3SHTPAT #chronicpain #AcutePain #NonOpioidMedication #ClinicalTrail #prophecy #marketresearch #prophecymarketinsights

Check out this week's Healthcare Report where we discuss news surrounding Eli Lilly and Company! Eli Lilly's Alzheimer's drug, donanemab, may outperform Leqembi in effectiveness and frequency of use. Charities have created SCI Ventures, an investment fund for spinal cord injury treatments. Also, comment your email address to be a part of our mailing list! Analyst: Pakhi Sahni

Happening Today... (and tomorrow) 📆 #BioTrinity is being held in London 👑 for a two days designed to connect people from early stage and emerging life sciences R&D companies, investors, big pharma, academics, charities, government, and service providers. 🔬 💊 💉 Thermo Fisher Scientific's Clinical Trial Division is being represented by Mike Hawkes ACMA and Dillan Vekaria. If you are attending and you have a question about how ThermoFisher can support your clinical trial be sure to connect with my colleagues. They can answer your questions related to #ComparatorSourcing #ClinicalSupplyOptimisation #ClinicalPackaging #IMPBlinding and #GlobalLogistics #clinicaltrials #drugdevelopment #patientfirst

We are deeply encouraged that REPAIR Impact Fund portfolio company Revagenix, Inc. has raised a Series B, which along with substantial non-dilutive financing will take multiple programs to clinical proof of concept. Novo Holdings was the sole investor in the Series A in 2020, and since then the management team has advanced several antibiotic discovery programs into late pre-clinical testing, and attracted Tenmile Capital to lead the Series B. Revagenix, like the bird Phoenix, rose from the ashes of the bankruptcy of Archaogen, which had successfully developed and launched the antibiotic Plazomicin. The team led by Ryan Cirz knows both what it takes to create a novel antibiotic but just as importantly also what doesn’t fly commercially and financially.  New members of the board of directors include Mike Lamprecht from Tenmile, Bruce Montgomery, an advisor to Novo Holdings, and Cristina Larkin, previously COO of Spero Therapeutics. Raising money for antibiotic companies is unbelievably difficult right now. The Revagenix management team has shown that with the right team and science it is still hard but possible. Further perspectives here: https://lnkd.in/d5HD7Egp

🌐 #RAREis Global Advocate Grant 2024 🗓 Deadline: May 31, 2024 Amgen’s #RAREis Global Advocate Grant is now accepting applications. This initiative aims to support and empower individuals and communities affected by rare diseases worldwide. To qualify for consideration, an organization must be considered a non-profit organization, focused on supporting the rare disease community outside of Amgen’s disease states, all funds will be used in the year received and no healthcare providers will be receiving benefit from this grant. Past grant awardees are eligible to reapply and receive repeat funding. For more details on how to apply, visit 2024 #RAREis Global Advocate Grant (rareiscommunity.com) #WeareBiotech #CommunitySupport #RareDiseases #GlobalAdvocacy #Empowerment #Grant

Looking for company NOMINATIONS for Biotech Week Boston Awards! Submission Deadline Extended to Friday, May 10. I am honored to be a judge again this year. The BWB Awards at Biotech Week Boston is a celebratory gala of networking, food, drink, and entertainment on September 23rd in Boston. The 2024 Award Categories Are: • START-UP OF THE YEAR - The Start-up of the Year award recognizes a burgeoning company that has blossomed into an industry leader through growth and innovation. Sponsored by Stratacuity. • DE&I INITIATIVE - The DE&I Initiative award recognizes an organization or group that has advanced diversity, equity, and inclusion in the workplace by championing the perspectives and contributions of employees representing marginalized groups. • BIOTECH INNOVATION – The Biotech Innovation award recognizes a company or organization that has conceived a new or advancing biopharmaceutical product, manufacturing process or ground-breaking technology that yielded significant results. • DEAL OF THE YEAR - The Deal of the Year award recognizes the companies and individuals involved in forming a transformative business partnership, such as a major drug-licensing agreement or a successful merger/acquisition deal between companies. • TALENT ACCELERATION - The Talent Acceleration award recognizes an organization that has shown exceptional aptitude for training workers to develop the skills they need to thrive in the rapidly growing biopharmaceutical industry. • SUSTAINABILITY INITIATIVE - The Sustainability Initiative award recognizes the company that best embodies the spirit of sustainability through a conscious effort to improve its environmental impact through policy, training, and innovation. • CLINICAL ADVANCE OF THE YEAR - The Clinical Advance of the Year award recognizes an emerging drug that has passed through clinical trials and is expected to have a ground-breaking impact on healthcare in the years to come. • LIFETIME ACHIEVEMENT AWARD - The Lifetime Achievement award recognizes an exceptional individual who has served the industry beyond the call of duty throughout a distinguished career. • BOSTON HIGHLIGHT - The Boston Highlight award recognizes a standout life-sciences organization or person based in the Boston area that has made a significant contribution to the biopharmaceutical industry over the past year. • TRANSFORMATIONAL THERAPY - The Transformational Therapy award recognizes innovation in the discovery, development, delivery, and/or market accessibility of an advanced-therapy drug product that is designed to treat rare diseases with currently unmet medical needs. https://lnkd.in/e68bdtcQ

I’m thrilled to share the news that SCI Ventures, which started with $27mn in commitments, is expected to raise $40mn by the end of the year. SCI Ventures is a philanthropic investment vehicle of five charities in the U.S., U.K., and E.U. aiming to develop technology solutions to help paralyzed people and those with spinal cord injuries communicate and restore mobility. SCI Ventures will be investing funds into companies working to cure paralysis so people injured today can become the first generation that doesn’t have to live with paralysis for the rest of their lives. Check out this article to learn more about their work and how this venture philanthropy effort operates: https://buff.ly/4ekkm1i #philanthropy #investing #business #SCIVentures